TITLE

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

AUTHOR(S)
McDonnell, David P.; Detke, Holland C.; Bergstrom, Richard F.; Kothare, Prajakti; Johnson, Jason; Stickelmeyer, Mary; Sanchez-Felix, Manuel V.; Sorsaburu, Sebastian; Mitchell, Malcolm I.
PUB. DATE
January 2010
SOURCE
BMC Psychiatry;2010, Vol. 10, p45
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections (< 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed "post-injection delirium/sedation syndrome" (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur. Methods: Healthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted to assess solubility of olanzapine pamoate in various media. Results: Injection administrators reported no unusual occurrences during the injection. No anomalies were found with the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in plasma than in other media such as those approximating the environment in muscle tissue. Conclusions: Manufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection technique) with subsequent seepage of the medication into the vasculature, which would produce higher than intended olanzapine concentrations and symptoms consistent with PDSS. Trial Registration: ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489
ACCESSION #
52838983

 

Related Articles

  • Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. Detke, Holland C.; McDonnell, David P.; Brunner, Elizabeth; Fangyi Zhao; Sorsaburu, Sebastian; Stefaniak, Victoria J.; Corya, Sara A. // BMC Psychiatry;2010, Vol. 10, p43 

    Background: An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation...

  • Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses. Ciudad, Antonio; Anand, Ernie; Berggren, Lovisa; Casillas, Marta; Schacht, Alexander; Perrin, Elena // Neuropsychiatric Disease & Treatment;2013, Vol. 9, p1737 

    Background: A considerable proportion of patients suffering from schizophrenia show suboptimal responses to oral antipsychotics due to inadequate adherence. Hence, they are likely to benefit from switching to a long-acting injectable formulation. These post hoc analyses assessed the clinical...

  • Intramuscular Olanzapine -- a UK case series of early cases. Bushe, Chris J; Taylor, Mark; Mathew, Mathew // Annals of General Psychiatry;2007, Vol. 6, p11 

    Background: Clinical trials assessing efficacy and safety of Intramuscular (IM) Olanzapine in acute schizophrenia and acute mania have previously been undertaken in studies required for drug registration in patients who were required to give informed consent. These patients may have less severe...

  • Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective. Rauch, Anna-Sophia; Fleischhacker, W. // CNS Drugs;2013, Vol. 27 Issue 8, p637 

    Antipsychotics are the mainstay of the long-term treatment of patients with schizophrenia. In this context, the evidence also supports the effectiveness of long-acting injections (LAIs) or depots of antipsychotics regarding their relapse-preventing properties. When a LAI formulation of...

  • Delirium In th e Elderly. Burock, Jeffiey M. // Medicine & Health Rhode Island;Jul2012, Vol. 95 Issue 7, p214 

    The article offers information on delirium. It states that it is often the initial manifestation of an underlying acute medical illness and may be present before signs such as fever, tachypnea, tachycardia or hypoxia.The patients at the highest risk for delirium include older patients with...

  • Zyprexa Relprevv Receives Attention After 2 Unexplained Deaths.  // Journal of Psychosocial Nursing & Mental Health Services;Aug2013, Vol. 51 Issue 8, p5 

    No abstract available.

  • Similarities and differences between the subchronic and withdrawal effects of clozapine and olanzapine on forelimb force steadiness. Stanford, John A.; Fowler, S. C. // Psychopharmacology;1997, Vol. 132 Issue 4, p408 

    Abstract The purpose of this study was to compare the subchronic, low-dose effects of clozapine with those of olanzapine in a learned behavioral task previously shown to distinguish between clozapine and haloperidol with acute and subchronic treatment regimes. Rats were trained to use a single...

  • Effects of antipsychotic drugs on operant responding after acute and repeated administration. Varvel, S.A.; Vann, R.E.; Wise, L.E.; Philibin, S.D. // Psychopharmacology;2002, Vol. 160 Issue 2, p182 

    Abstract Rationale: The current generation of atypical antipsychotic drugs represents an improvement over tra-ditional ('typical') antipsychotics in many respects. However, a theoretical framework and adequate preclini-cal models have not yet been developed to predict or ex-plain ...

  • Metabolic impact a key factor in antipsychotics' cost effectiveness.  // PharmacoEconomics & Outcomes News;6/25/2011, Issue 631, p4 

    The article discusses the cost-effectiveness of using the antipsychotic drug aripiprazole compared with olanzapine in patients with schizophrenia or bipolar disorders based on research from i3 Innovus, Bristol-Myers Squibb and the Karolinska Institut.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics